The present study aimed to target allergen-specific B cells in a chronic HDM allergy model, using a protein-engineered chimeric molecule, capable of the simultaneous engagement of BCR and CD32, as a novel therapeutic approach. The gene discussed is FCGR2B; the disease is Allergy.